The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Cited by (614)

Items 601–614 of 614

1. Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer
   Vladimir Stojšić, Bojan Zarić, Petar Simurdić, Tomi Kovačević, Darijo Bokan, Jelena Djekić Malbaša, Tatjana Šarčev, Goran M. Stojanović, Daliborka Bursać, Borislava Nikolin · 2026 · Radiology and Oncology
2. QinZhuLiangXue gel alleviates psoriasiform inflammation through immunomodulatory effects involving PD-1/PD-L1/SHP2 signaling axis
   Weixuan Yuan, Suting Sun, Tianyou Ma, Mengji Xie, Yu Huang, Le Kuai, Ying Luo, Jiankun Song, Xiaojie Ding, Yi Ru et al. · 2026 · Journal of Ethnopharmacology
3. Shaoyao Decoction Inhibits Colorectal Cancer Progression by Targeting PD-L1 to Reprogram the Immunosuppressive Tumor Microenvironment
   Xiaoyan Wang, Zhuoga Mima, Wujie Sai, Lijuan Song, Hao Li · 2026 · Applied Biochemistry and Biotechnology
4. Hyperinflammation and immunomodulation in influenza, SARS-CoV-2 and syncytial respiratory virus infection in adults: from innate immune responses and biomarkers to clinical and therapeutic implications
   Jesús Alonso‐Carrillo, Marta Obra Pinacho, Mario Cereza Latre, María Ruiz‐Ruigómez, Carlos Lumbreras, Antonio Lalueza · 2026 · Frontiers in Microbiology
5. Immune Checkpoint Inhibitors and Related Immunotherapies
   Sara Machado, Américo Cardoso · 2026 · Advances in computational intelligence and robotics book series
6. Purification of Bioactive Natural Antibodies to PD-1 Known as Regulatory Rheumatoid Factor from Human Blood Plasma
   Daria Menshikova, Alexey Terentiev, Pavel Ivanov, Alexandr Cherednichenko, Liubov Beduleva · 2026 · Antibodies
7. BindingDB Entry 50010878: Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
   BindingDB · 2021 · UC San Diego
8. BindingDB Entry 50011592: Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo.
   BindingDB · 2022 · UC San Diego
9. BindingDB Entry 50020204: Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.
   BindingDB · 2024 · UC San Diego
10. BindingDB Entry 50019139: Recent advances in small molecule based cancer immunotherapy.
    BindingDB · 2024 · UC San Diego
11. BindingDB Entry 50008457: Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction.
    BindingDB · 2026 · UC San Diego
12. BindingDB Entry 50021462: Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
    BindingDB · 2025 · UC San Diego
13. BindingDB Entry 50021974: Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction.
    BindingDB · 2025 · UC San Diego
14. Checkpoint Pathways in Childhood Cleft Lip and Palate—Associations of PD1 and CTLA4 with Clinical Parameters
    Margareta Budner, Kamil Torres, Violetta Opoka‐Winiarska, Agnieszka Lasota, Małgorzata Gdak, Paulina Mertowska, Sebastian Mertowski, Krzysztof Gosik, M. S. Kang, Tomasz Kamil Urbanowicz et al. · 2026 · International Journal of Molecular Sciences